Dr Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in US
Hyderabad: Drugmaker, Dr. Reddy's Laboratories Ltd., has announced the launch of the company's Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).
Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Fesoterodine fumarate extended-release tablets are indicated for the treatment of Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
The Toviaz brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022 according to IQVIA.
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30. Toviaz is a trademark of Pfizer Inc.
Read also: Dr Reddys aims to triple reach to 1.5 billion patients by 2030
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.